Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3241417 | 0.79 | EPHX2 (0.60) | MEN1KMT2AP2RX7EPHX2HSD11B1 | |
| SCHEMBL31276530 | 0.79 | CXCR3 (0.42) | MEN1KMT2AP2RX7HSD11B1MAPK1 | |
| SCHEMBL7834289 | 0.79 | MEN1 (0.38) | MEN1KMT2AP2RX7EPHX2 | |
| SCHEMBL7252476 | 0.79 | SMN1; SMN2 (0.58) | MEN1KMT2AP2RX7EPHX2HSD11B1 | |
| SCHEMBL11447312 | 0.79 | ALDH1A1 (0.52) | MEN1KMT2AP2RX7ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL11455404 | 0.78 | ALDH1A1 (0.50) | MEN1KMT2AP2RX7ALDH1A1TSHR | |
| SCHEMBL8056506 | 0.77 | MEN1 (0.59) | MEN1KMT2AP2RX7EPHX2ALDH1A1 | |
| SCHEMBL28060952 | 0.76 | EPHX2 (0.57) | MEN1KMT2AP2RX7EPHX2HSD11B1 | |
| SCHEMBL10067533 | 0.75 | P2RX7 (0.67) | MEN1KMT2AP2RX7EPHX2ALDH1A1 | |
| SCHEMBL13148563 | 0.74 | P2RX7 (0.49) | MEN1KMT2AP2RX7EPHX2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112480305-A | Adamantyl phenyl sulfonate based polymeric flame retardant, preparation method and application | 广东知塑新材料有限公司 | 2021-03-12 | — | — | CN | claimed |
| CN-101128421-A | Methods and compositions for treating amyloid-related diseases | NEUROCHEM INTERNAT LTD (CH) | 2008-02-20 | — | — | CN | claimed |
| EP-1836161-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | Neurochem (International) Limited (CH) | 2007-09-26 | — | — | EP | claimed |
| WO-2006085149-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | WO | claimed |
| EP-0370320-B1 | LACTAMIMIDES IN THE TREATMENT OF DRUG-RESISTANT PROTOZOAL INFECTIONS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-09-30 | — | — | EP | claimed |
| EP-0370320-A1 | Lactamimides in the treatment of drug-resistant protozoal infections | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-05-30 | — | — | EP | claimed |
| CN-117945964-A | Synthesis method of aryl alkyl asymmetric thioether | 中国人民解放军军事科学院防化研究院 | 2024-04-30 | — | — | CN | disclosed |
| EP-1836161-B1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BHI LTD PARTNERSHIP (CA) | 2016-07-20 | — | — | EP | disclosed |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2014-11-06 | — | — | US | disclosed |
| US-8835654-B2 | Method and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-09-16 | — | — | US | disclosed |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-8044100-B2 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH INC. (CA) | 2011-10-25 | — | — | US | disclosed |
| US-7855241-B2 | Method of improving abrasion resistance of plastic article using nanoparticles and article produced thereby | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2010-12-21 | — | — | US | disclosed |
| US-20070088095-A1 | Method of improving abrasion resistance of plastic article using nanoparticles and article produced thereby | GENERAL ELECTRIC COMPANY (US) | 2007-04-19 | — | — | US | disclosed |
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-10-05 | — | — | US | disclosed |
| WO-2006085149-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | WO | disclosed |
| US-4200588-A | ANTILIPEMIC AGENTS, ANTIATHEROSCLEROTIC | THE UPJOHN COMPANY (US) | 1980-04-29 | — | — | US | disclosed |
| US-4130561-A | Polycycloanilines | THE UPJOHN COMPANY (US) | 1978-12-19 | — | — | US | disclosed |
| US-4120899-A | HYPOLIPEDEMIC, ANTIATHEROSCLEROTIC | THE UPJOHN COMPANY (US) | 1978-10-17 | — | — | US | disclosed |
| US-4036977-A | HYPOLIPEDEMIC AND ANTIATHEROSCLEROTIC PROPERTIES | THE UPJOHN COMPANY (US) | 1977-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223855-A1 | reduces or inhibits amyloid fibril formation, organ specific dysfunction (e.g., neurodegeneration), or cellular toxicity | APP, IAPP, BACE1 | MEN1 2282/4885KMT2A 4826/4885P2RX7 3008/4885 |
| US-20140329746-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | MEN1 1011/4885KMT2A 4192/4885P2RX7 1367/4885 |
| US-20120015911-A1 | METHOD AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | MEN1 683/4885KMT2A 4354/4885P2RX7 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.